Push-Through Strip is a Child-Resistant, Senior-Friendly Barrier Package
Romaco Siebler and Huhtamaki will premiere a push-through strip packaging for pharmaceuticals at CPhI WorldWide 2018.
Image courtesy Romaco
The film and foil specialist Romaco Siebler and its partner Huhtamaki will premiere a push-through strip packaging for pharmaceuticals at CPhI WorldWide 2018. The tablets can be removed simply by pressing them out of the pockets in the four-sided sealed foil pack, combining the barrier properties of strip packaging with the opening mechanism of blister formats. The push-through strip uses less material than cold-formed aluminium blisters.
The strips are manufactured either from a multilayer laminated structure or from a transparent barrier foil. The material does not tear and can therefore be regarded as child resistant. A targeted perforation of the upper polyester layer allows the pack to be opened by pressing the tablet out of the laminated foil with the thumb. The push-through strips are also senior friendly and a good alternative to tear-open strip packaging or aluminium-aluminium blisters. Huhtamaki has a patent pending for the manufacturing process used for this special foil.
Romaco’s push-through strips can be supplied either in the standard rectangular format or as ‘design’ strips. A Siebler HM 1-350 heat-sealing machine equipped with a special die-cutter is used to manufacture special formats. The continuous cutting station supports both round strip formats and heart, petal, or star shapes. The equipment achieves a maximum output of 800 design strips per minute. The production of push-through strips in a heat-sealing process expands Romaco’s portfolio in the area of air, light, and moisture-tight unit dose packaging.
At the upcoming CPhI Worldwide in Madrid, Romaco will share a booth with its industry partner Huhtamaki (Stand 2A43).
Source: Romaco
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
